This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Henry H. Balfour, Jr, MD; Carol L. Balfour, RN; Charlene K. Edelman; Phillip A. Rierson, MD

Am J Dis Child. 1976;130(10):1089-1091.

Abstract
• Because the Wistar RA27/3 strain rubella virus vaccine has potentially important advantages over rubella vaccines currently licensed in the United States, a field trial was conducted in Minnesota and Wisconsin in 1974 to evaluate RA27/3 in this country. Two hundred eighty-five (99.7%) of 286 susceptible children given RA27/3 subcutaneously seroconverted, with a geometric mean hemagglutination inhibition (HI) titer of 81.2. Twenty-eight (23%) of 122 children with rubella antibodies before immunization had fourfold or greater rises in rubella HI titers. The highest percentage of booster responses occurred in children with low preimmunization titers. Side effects were reported in 34% of subjects, but only one reaction associated with RA27/3 was serious: in a 5-year-old boy, arthritis of the left hip developed 31 days after immunization. This study indicates that RA27/3 vaccine produced a very high rate of seroconversion with high postimmunization HI titers. The ability to elicit significant booster responses in children with low levels of HI antibodies suggests that RA27/3 could be used to boost immunity in women of childbearing age whose rubella titers have declined to undetectable levels.

(Am J Dis Child 130:1089-1091, 1976)

Author Affiliations
From the departments of laboratory medicine and pathology, and pediatrics, University of Minnesota Health Sciences Center (Drs Balfour and Ms Edelman), and the Southdale Pediatrics Associates (Dr Rierson), Minneapolis.

Footnotes
Deceased.

Reprint requests to Box 437 Mayo Memorial Bldg, University of Minnesota, Minneapolis, MN 55455 (Dr Balfour).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevalence of Poliovirus Neutralizing Antibodies in Young Adult Women
Mayer and Balfour
JAMA 1981;246:1207-1209.
ABSTRACT  

RA27/3 Rubella Vaccine: A Four-Year Follow-up
Balfour et al.
Arch Pediatr Adolesc Med 1980;134:350-353.
ABSTRACT  

Rubella Reimmunization Now
BALFOUR
Arch Pediatr Adolesc Med 1979;133:1231-1233.
ABSTRACT  

Rubella Vaccination-Reply
BALFOUR and AMREN
Arch Pediatr Adolesc Med 1979;133:1202-1203.
ABSTRACT  

Rubella, Measles and Mumps Antibodies Following Vaccination of Children: A Potential Rubella Problem
Balfour and Amren
Arch Pediatr Adolesc Med 1978;132:573-577.
ABSTRACT